38 Results for "

deposits

" in MedChemExpress (MCE) Product Catalog:
Products (38)

38 Results for "deposits" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-139066
CAS No.: 544-72-9
Purity:  ≥98.0%
Synonyms: Trichosanic acid
Punicic acid is a bioactive compound of pomegranate seed oil. Punicic acid is an isomer of conjugated α-linolenic acid and ω-5 polyunsaturated fatty acids. Punicic acid has anti-inflammatory and antioxidant activities and can inhibit the expression of inflammatory mediators such as tumor necrosis factor α (TNF-α). Punicic acid can also reduce the formation of β-amyloid deposits and hyperphosphorylation of tau by increasing the expression of GLUT4 protein and inhibiting the overactivation of calpain, and is used to prevent and treat neurodegenerative diseases. In addition, punicic acid also has breast cancer inhibitor properties that depend on lipid peroxidation and PKC pathways .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W013570
CAS No.: 208-96-8
Acenaphthylene is a polycyclic aromatic hydrocarbon (PAH). PAHs are derived naturally from coal and tar deposits, and produced by incomplete combustion of organic matter .
loading...
    loading...
Cat. No.: HY-W015650
CAS No.: 19005-93-7
Indole-2-carbaldehyde is an indole derivative that can be used to reduce or remove localized fat deposits and/or tighten loose skin and soft tissues. Indole-2-carbaldehyde can be isolated from the fermentation broth of the coral symbiotic actinomycete Pseudonocardia sp. SCSIO 11457 and is used in cosmetic applications or pharmaceutical production .
loading...
    loading...
Cat. No.: HY-P10709
CAS No.: 847058-45-1
Target:  

Collagen

Research Areas:  

Cardiovascular Disease Cancer

CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects .
loading...
    loading...
Cat. No.: HY-P991128
CAS No.: 2965214-50-8
Synonyms: NI-006; ALXN2220
Cliramitug (NI-006; ALXN2220) is a monoclonal antibody that targets human transthyretin (TTR). Cliramitug binds to TTR and inhibits its amyloidogenic process, exerting amyloid formation-inhibiting activity. Cliramitug can be used in the research of transthyretin amyloidosis-related diseases, such as certain neurological and cardiovascular diseases .
loading...
    loading...
Cat. No.: HY-126192
CAS No.: 566169-93-5
Purity:  ≥95.0%
Synonyms: PiB; 6-OH-BTA-1
Pittsburgh Compound B (PiB) is a blood-brain barrier-permeable, specific deposition PET tracer that binds to Aβ(1-40) fibrils with a Ki value of 678.4 nM. Through click chemical modification (a clickable Pittsburgh Compound B derivative is prepared by introducing a PEG3 linker and an alkynyl group at the 6-hydroxy site of Pittsburgh Compound B, followed by covalent conjugation with azide-labeled fluorescent dyes or affinity tags via copper-catalyzed azide-alkyne cycloaddition (CuAAC)), Pittsburgh Compound B and its conjugates can be used for fluorescence imaging, ultrastructural studies, and enrichment and characterization of Aβ complexes. Pittsburgh Compound B is applicable to Alzheimer's disease research .
loading...
    loading...
Cat. No.: HY-P99358
CAS No.: 1662664-56-3
Synonyms: GSK 2398852; Anti-Serum Amyloid P/SAP Reference Antibody (dezamizumab)

Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Dezamizumab (GSK 2398852) is a fully humanized clonal IgG1 antibody against serum amyloid P component (SAP) with complement activation and amyloid clearance-inducing activities. Dezamizumab binds to SAP associated with amyloid deposits to form complexes that activate complement and mediate phagocytic clearance, triggering activation of the classical complement pathway. Dezamizumab can be used for the research of systemic amyloidosis .
loading...
    loading...
Cat. No.: HY-N6660
CAS No.: 621-71-6
Synonyms: Tricaprin; Glyceryl tridecanoate
Trisdecanoin (Tricaprin; Glyceryl tridecanoate) is an orally available precursor of decanoic acid (DA precursor) that can be hydrolyzed to decanoic acid. Trisdecanoin and its metabolite capric acid not only provide the body with a quick source of energy, but can also affect lipid metabolism. Trisdecanoin is a major component of medium chain triglycerides (MCT), which has preventive or inhibitory properties for abdominal aortic aneurysms (AAA), inhibition of cardiovascular disease, and anti-androgen (NSAA) and anti-hyperglycemic properties. Trisdecanoin can be used as an additive in food, medicine and cosmetics .
loading...
    loading...
Cat. No.: HY-D1353
CAS No.: 1382764-52-4
LipidGreen 2 is a second generation small molecule probe for lipid imaging. LipidGreen 2 has a better fluorescence signal compared with the previous LipidGreen, and selectively stains neutral lipids in cells and fat deposits in live zebrafish .
loading...
    loading...
Cat. No.: HY-P99105
CAS No.: 2414866-63-8
Synonyms: CAEL-101

Research Areas:  

Neurological Disease

Anselamimab (CAEL-101) is a chimeric monoclonal antibody for systemic light chain (AL) amyloidosis. Anselamimab can promote phagocytic destruction and subsequent clearance of amyloid deposits. Anselamimab can be used in the research of amyloidosis .
loading...
    loading...
Cat. No.: HY-P4882A
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

(Pyr3)-Amyloid β-Protein (3-42) TFA is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) TFA is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .
loading...
    loading...
Cat. No.: HY-P99164
CAS No.: 2019133-28-7
Synonyms: LY3303560

Target:  

Tau Protein

Research Areas:  

Neurological Disease

Zagotenemab (LY3303560) is a humanized anti-tau antibody that selectively binds and neutralises tau deposits in the brain. Zagotenemab can be used in Alzheimer's disease research .
loading...
    loading...
Cat. No.: HY-P1047
CAS No.: 182912-74-9
Synonyms: [Pro18, Asp21] β-Amyloid (17-21)
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

β-Sheet Breaker Peptide iAβ5 is an effective brain amyloid-β (Abeta) degrader. Abeta deposits are associated with Alzheimer's disease (AD), and the related toxicity arises from its β-sheet conformation and aggregation. β-Sheet Breaker Peptide iAβ5 can repeatedly induce the degradation of fibrillary amyloid deposits in vivo. Therefore, β-Sheet Breaker Peptide iAβ5 can prevent and/or reverse neuronal contraction caused by Abeta and reduce the range of interleukin IL-1beta positive microglial-like cells around Abeta deposits. β-Sheet Breaker Peptide iAβ5 can reduce the size and/or number of brain amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 is labeled with a hydrophobic benzyl alcohol (HBA) tag and shows a bright blue color under acidic conditions, which can be used for quantitative determination.
loading...
    loading...
Cat. No.: HY-P1173
CAS No.: 706785-93-5
Synonyms: Myristoylated L 803; GSK-3β Inhibitor XIII
Target:  

GSK-3 Amyloid-β

Research Areas:  

Neurological Disease

L803-mts (Myristoylated L 803) is a selective and substrate-competitive GSK-3 peptide inhibitor (IC50: 40 μM). L803-mts also reduces Aβ deposits and ameliorates cognitive deficits in 5XFAD mice. L803-mts shows antidepressive effect in the forced swimming test .
loading...
    loading...
Cat. No.: HY-P4767
CAS No.: 198328-30-2
Target:  

Amylin Receptor

Research Areas:  

Metabolic Disease

Amylin (1-13) (human) is a fragment and a residues within amyloid cores of Amylin (human IAPP). Amylin is a glucose-regulating hormone, deposits as amyloid fibrils in condition of type II diabetes (T2D). Amylin (1-13) (human) has no effect on firbl formation, as it cannot form fibrils by itself .
loading...
    loading...
Cat. No.: HY-P1387
CAS No.: 144409-98-3
Target:  

Amyloid-β Apoptosis

Research Areas:  

Neurological Disease

β-Amyloid (1-40) (rat) is a rat form of the amyloid β-peptide, which accumulates as an insoluble extracellular deposit around neurons, giving rise to the senile plaques associated with Alzheimer's disease (AD). β-Amyloid (1-40) (rat) increases 45Ca 2+ influx, induces neurodegeneration in the rat hippocampal neurons of the CA1 subfield. β-Amyloid (1-40) (rat) induces apoptosis. β-Amyloid (1-40) (rat) can be used for the research of Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-148547
CAS No.: 1352477-22-5
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

q-FTAA is an oligothiophene. q-FTAA competes for binding to the X-34 binding site on fibrils. q-FTAA is applicable to research related to Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-W013570S
CAS No.: 93951-97-4
Synonyms: Acenaphthylene-d8
Acenaphthylene-d8 is the deuterium labeled Acenaphthylene . Acenaphthylene is a polycyclic aromatic hydrocarbon (PAH). PAHs are derived naturally from coal and tar deposits, and produced by incomplete combustion of organic matter .
loading...
    loading...
Cat. No.: HY-P3846
CAS No.: 1802086-22-1
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-177739
CAS No.: 1590409-23-6
Research Areas:  

Inflammation/Immunology

Antifibrotic agent 2 (Compound 636) is a polycyclic pyridinone derivative with antifibrotic activity. Antifibrotic agent 2 reduces the pathological accumulation of fibrosis-related proteins such as fibronectin and collagen, prevents excessive fibrous connective tissue from depositing in organs or tissues, and reverses or delays the remodeling of tissue fibrosisby regulating the abnormal proliferation and activation of fibroblasts. Antifibrotic agent 2 can be used for research on pulmonary fibrosis .
loading...
    loading...